Liu Y - Search Results

1

Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.

Xiang J, Wang Y, Wang W, Yu J, Zheng L, Hong Y, Shi L, Zhang C, Chen N, Xu J, Gong X, Zhang Z, Cui H, Zhou Q, Zhang D, Liu Y, Ke Y, Shen J, Xia G, Bai X. Xiang J, et al. Among authors: liu y. Bioorg Chem. 2023 Nov;140:106765. doi: 10.1016/j.bioorg.2023.106765. Epub 2023 Aug 7. Bioorg Chem. 2023. PMID: 37582330

2

A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.

Xia G, Chen W, Zhang J, Shao J, Zhang Y, Huang W, Zhang L, Qi W, Sun X, Li B, Xiang Z, Ma C, Xu J, Deng H, Li Y, Li P, Miao H, Han J, Liu Y, Shen J, Yu Y. Xia G, et al. Among authors: liu y. J Med Chem. 2014 Dec 11;57(23):9889-900. doi: 10.1021/jm5014659. Epub 2014 Dec 1. J Med Chem. 2014. PMID: 25409491

3

Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.

Zhao F, Zhang J, Zhang L, Hao Y, Shi C, Xia G, Yu J, Liu Y. Zhao F, et al. Among authors: liu y. Bioorg Med Chem. 2016 Sep 15;24(18):4281-4290. doi: 10.1016/j.bmc.2016.07.019. Epub 2016 Jul 12. Bioorg Med Chem. 2016. PMID: 27448775

4

Erratum to "Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase" [Bioorg. Med. Chem. 24 (2016) 4281-4290].

Zhao F, Zhang J, Zhang L, Hao Y, Shi C, Xia G, Yu J, Liu Y. Zhao F, et al. Among authors: liu y. Bioorg Med Chem. 2017 May 15;25(10):2811-2812. doi: 10.1016/j.bmc.2017.03.042. Epub 2017 Apr 5. Bioorg Med Chem. 2017. PMID: 28389111 No abstract available.

5

Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.

Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ. Zhao F, et al. Among authors: liu yj. Eur J Med Chem. 2017 Jul 7;134:147-158. doi: 10.1016/j.ejmech.2017.03.085. Epub 2017 Apr 4. Eur J Med Chem. 2017. PMID: 28411455

6

Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.

Shi C, Wang Q, Liao X, Ge H, Huo G, Zhang L, Chen N, Zhai X, Hong Y, Wang L, Han Y, Xiao W, Wang Z, Shi W, Mao Y, Yu J, Xia G, Liu Y. Shi C, et al. Among authors: liu y. Eur J Med Chem. 2019 Sep 15;178:352-364. doi: 10.1016/j.ejmech.2019.06.005. Epub 2019 Jun 4. Eur J Med Chem. 2019. PMID: 31200237

7

The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.

Zhang L, Mao Y, Gao Z, Chen X, Li X, Liu Y, Xia G. Zhang L, et al. Among authors: liu y. Eur J Drug Metab Pharmacokinet. 2020 Feb;45(1):15-26. doi: 10.1007/s13318-019-00573-9. Eur J Drug Metab Pharmacokinet. 2020. PMID: 31494843

8

Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys.

Mao Y, Zhang L, Li H, Li X, Liu Y, Xia G. Mao Y, et al. Among authors: liu y. Regul Toxicol Pharmacol. 2019 Dec;109:104484. doi: 10.1016/j.yrtph.2019.104484. Epub 2019 Oct 1. Regul Toxicol Pharmacol. 2019. PMID: 31585137

9

SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.

Liao X, Hong Y, Mao Y, Chen N, Wang Q, Wang Z, Zhang L, Wang L, Shi C, Shi W, Ge H, Li A, Li X, Xia G, Liu Y. Liao X, et al. Among authors: liu y. Cancer Sci. 2020 May;111(5):1761-1773. doi: 10.1111/cas.14367. Epub 2020 Mar 24. Cancer Sci. 2020. PMID: 32103527 Free PMC article.

10

A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis.

Yang T, Wang Z, Wu F, Tan J, Shen Y, Li E, Dai J, Shen R, Li G, Wu J, Wang L, Wang H, Liu Y. Yang T, et al. Among authors: liu y. PLoS Comput Biol. 2010 Feb 5;6(2):e1000669. doi: 10.1371/journal.pcbi.1000669. PLoS Comput Biol. 2010. PMID: 20140191 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206,011 results

Search Page

Filters